KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Companyâs biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Companyâs product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļKALA
āļāļ·āđāļāļāļĢāļīāļĐāļąāļKALA BIO Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 20, 2017
āļāļĩāļāļĩāđāļLazar (David Elliot)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ38
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 20
āļāļĩāđāļāļĒāļđāđ1167 Massachusetts Avenue
āđāļĄāļ·āļāļARLINGTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02476
āđāļāļĢāļĻāļąāļāļāđ17819965252
āđāļ§āđāļāđāļāļāđhttps://www.kalarx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļKALA
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 20, 2017
āļāļĩāļāļĩāđāļLazar (David Elliot)
Mr. David Elliot Lazar
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
Mr. Darius Kharabi
Chief Business Officer
Dr. Kim Brazzell, Ph.D.
Head of Research and Development, Chief Medical Officer
Head of Research and Development, Chief Medical Officer
Mr. Howard B. (Howie) Rosen
Mr. Howard B. (Howie) Rosen
Independent Director
Mr. Mark T. Iwicki
Director
Mr. Andrew Ian Koven
Lead Independent Director
Lead Independent Director
Mr. Todd M. Bazemore
Director
Mr. C. Daniel Myers
Independent Director
Dr. Marjan Farid, M.D.
Independent Director
Ms. Taylor Steiner
Investor Relations
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. David Elliot Lazar
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
Mr. Darius Kharabi
Chief Business Officer
Dr. Kim Brazzell, Ph.D.
Head of Research and Development, Chief Medical Officer
Head of Research and Development, Chief Medical Officer
Mr. Howard B. (Howie) Rosen
Mr. Howard B. (Howie) Rosen
Independent Director
Mr. Mark T. Iwicki
Director
Mr. Andrew Ian Koven
Lead Independent Director
Lead Independent Director